Key result
Surgical resection plus adjuvant Pola-R-CHP achieves complete remission of primary cardiac lymphoma at 8 months.
Why the study?
Does emergency surgical resection combined with adjuvant Pola-R-CHP chemotherapy prevent recurrence in a patient with primary cardiac lymphoma?
Case Report (n=1)
No
Does emergency surgical resection combined with adjuvant Pola-R-CHP chemotherapy prevent recurrence in a patient with primary cardiac lymphoma?
A multimodal approach combining emergency surgical debulking and targeted immunochemotherapy (Pola-R-CHP) achieved short-term disease-free survival in a patient with a rare primary cardiac lymphoma.
May support surgery plus Pola-R-CHP in select primary cardiac lymphoma; hypothesis-generating case report requiring prospective validation.
Primary cardiac lymphoma is a highly rare type of malignant tumor that originates from the lymphoid tissue within the heart or pericardium. Surgical treatment is the primary method for obtaining pathological results and relieving obstructions, and chemotherapy is the main method for disease control. We present a case of a 67-year-old woman diagnosed with primary cardiac lymphoma, presenting with shortness of breath and bilateral lower extremity edema after activity. Multimodality imaging results suggest a primary cardiac lymphoma, which was located in the right atrioventricular groove. Surgical resection of the mass was performed and histopathology confirmed the diagnosis of primary cardiac lymphoma. Based on the genetic results, Pola-R-CHP was used for postoperative chemotherapy. Fortunately, no evidence of recurrence of primary cardiac lymphoma was showed 8 months after surgery. Surgical resection combined with chemotherapy has achieved satisfactory results in the treatment of primary cardiac lymphoma.
No takes yet. Share an insight, caveat, or question.
Zhu et al. (2026) conducted a case report in Primary cardiac lymphoma (n=1). Surgical resection and Pola-R-CHP chemotherapy was evaluated on Recurrence or residual disease at 8 months. Surgical resection combined with postoperative Pola-R-CHP chemotherapy successfully treated primary cardiac lymphoma, showing no evidence of recurrence or residual disease at 8 months follow-up.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Frontiers in Oncology